BioLife Solutions (BLFS) 10-Q 11 May 23 2023 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2023	May 01, 2023
Document Information [Line Items]
Entity Central Index Key	0000834365
Entity Registrant Name	BIOLIFE SOLUTIONS INC
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-36362
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	94-3076866
Entity Address, Address Line One	3303 Monte Villa Parkway, Suite 310
Entity Address, City or Town	Bothell
Entity Address, State or Province	WA
Entity Address, Postal Zip Code	98021
City Area Code	425
Local Phone Number	402-1400
Title of 12(b) Security	BioLife Solutions, Inc. Common Stock
Trading Symbol	BLFS
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		43,456,275

Unaudited Condensed Consolidate

Unaudited Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 19,105	$ 19,442
Restricted cash	31	31
Available-for-sale securities, current portion	35,780	43,260
Accounts receivable, trade, net of allowance for doubtful accounts of $956 and $739 as of March 31, 2023 and December 31, 2022, respectively	30,343	33,936
Inventories	41,329	34,904
Prepaid expenses and other current assets	6,201	6,879
Total current assets	132,789	138,452
Assets held for rent, net	9,005	9,064
Property and equipment, net	26,100	23,638
Operating lease right-of-use assets, net	15,592	15,292
Financing lease right-of-use assets, net	242	272
Long-term deposits and other assets	284	281
Available-for-sale securities, long-term	2,019	1,332
Equity investments	5,069	5,069
Total intangible assets, net	30,629	32,088
Goodwill	224,741	224,741
Total assets	446,470	450,229
Current liabilities:
Accounts payable	15,525	15,367
Accrued expenses and other current liabilities	10,701	9,782
Sales taxes payable	4,585	4,151
Warranty liability	8,895	8,312
Lease liabilities, operating, current portion	2,906	2,860
Lease liabilities, financing, current portion	161	158
Debt, current portion	1,250	1,814
Contingent consideration, current portion	3,296	2,138
Total current liabilities	47,319	44,582
Contingent consideration, long-term	1,880	2,318
Lease liabilities, operating, long-term	15,114	14,962
Lease liabilities, financing, long-term	95	126
Debt, long-term	23,692	23,793
Deferred tax liabilities	263	250
Other long-term liabilities	0	10
Total liabilities	88,363	86,041
Commitments and contingencies (Note 12)
Shareholders’ equity:
Preferred stock, $0.001 par value; 1,000,000 shares authorized, Series A, 4,250 shares designated, and 0 shares issued and outstanding as of March 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 150,000,000 shares authorized, 43,289,969 and 42,832,231 shares issued and outstanding, respectively, as of March 31, 2023 and December 31, 2022	43	43
Additional paid-in capital	619,227	611,739
Accumulated other comprehensive loss, net of taxes	(534)	(679)
Accumulated deficit	(260,629)	(246,915)
Total shareholders’ equity	358,107	364,188
Total liabilities and shareholders’ equity	$ 446,470	$ 450,229

Unaudited Condensed Consolida_2

Unaudited Condensed Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable, allowance for doubtful accounts	$ 956	$ 739
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, authorized (in shares)	150,000,000	150,000,000
Common stock, issued (in shares)	43,289,969	42,832,231
Common stock, outstanding (in shares)	43,289,969	42,832,231
Series A Preferred Stock [Member]
Preferred stock, shares designated (in shares)	4,250	4,250
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0

Unaudited Condensed Consolida_3

Unaudited Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenue	$ 37,703	$ 36,220
Costs and operating expenses:
General and administrative	14,842	11,530
Sales and marketing	6,471	4,891
Research and development	4,152	3,781
Intangible asset amortization	1,459	2,863
Acquisition costs	0	11
Change in fair value of contingent consideration	720	(3,335)
Total operating expenses	51,308	44,187
Operating loss	(13,605)	(7,967)
Other expense:
Interest expense, net	(411)	(184)
Other income	394	131
Total other expense, net	(17)	(53)
Loss before income tax (expense) benefit	(13,622)	(8,020)
Income tax (expense) benefit	(92)	599
Net loss	(13,714)	(7,421)
Net loss attributable to common shareholders:
Basic and Diluted	$ (13,714)	$ (7,421)
Basic and Diluted (in dollars per share)	$ (0.32)	$ (0.18)
Weighted average shares used to compute loss per share attributable to common shareholders:
Basic and Diluted (in shares)	43,027,612	42,014,055
Product [Member]
Revenue	$ 31,593	$ 30,388
Costs and operating expenses:
Cost of goods and services	18,397	20,384
Service Revenue [Member]
Revenue	4,471	3,090
Costs and operating expenses:
Cost of goods and services	3,891	2,145
Rental Revenue [Member]
Revenue	1,639	2,742
Costs and operating expenses:
Cost of goods and services	$ 1,376	$ 1,917

Unaudited Condensed Consolida_4

Unaudited Condensed Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net (loss) income	$ (13,714)	$ (7,421)
Other comprehensive income (loss):
Foreign currency translation adjustment, net of tax	106	(156)
Unrealized gain on available-for-sale securities, net of tax	39	0
Comprehensive loss	$ (13,569)	$ (7,577)

Unaudited Condensed Consolida_5

Unaudited Condensed Consolidated Statements of Shareholders' Equity - USD ($) $ in Thousands	Preferred Stock [Member] Series A Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Total
Balance (in shares) at Dec. 31, 2021	0	41,817,503
Balance at Dec. 31, 2021	$ 0	$ 42	$ 585,397	$ (282)	$ (107,110)	$ 478,047
Stock-based compensation	$ 0	$ 0	5,399	0	0	5,399
Stock option exercises (in shares)	0	129,933
Stock option exercises	$ 0	$ 0	257	0	0	257
Stock issued – on vested RSAs (in shares)		383,646
Stock issued – on vested RSAs			0	0	0	0
Foreign currency translation	0	0	0	(156)	0	(156)
Net (loss) income	0	0	0	0	(7,421)	(7,421)
Fees incurred for registration filings	$ 0	$ 0	(51)	0	0	(51)
Balance (in shares) at Mar. 31, 2022	0	42,331,082
Balance at Mar. 31, 2022	$ 0	$ 42	591,002	(438)	(114,531)	476,075
Balance (in shares) at Dec. 31, 2022	0	42,832,231
Balance at Dec. 31, 2022	$ 0	$ 43	611,739	(679)	(246,915)	364,188
Stock-based compensation	$ 0	$ 0	7,363	0	0	7,363
Stock option exercises (in shares)	0	80,938
Stock option exercises	$ 0	$ 0	125	0	0	125
Stock issued – on vested RSAs (in shares)	0	376,800
Stock issued – on vested RSAs	$ 0	$ 0	0	0	0	0
Foreign currency translation	0	0	0	106	0	106
Unrealized gain on available-for-sale securities	0	0	0	39	0	39
Net (loss) income	$ 0	$ 0	0	0	(13,714)	(13,714)
Balance (in shares) at Mar. 31, 2023	0	43,289,969
Balance at Mar. 31, 2023	$ 0	$ 43	$ 619,227	$ (534)	$ (260,629)	$ 358,107

Unaudited Condensed Consolida_6

Unaudited Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities
Net (loss) income	$ (13,714)	$ (7,421)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation	1,721	1,653
Amortization of intangible assets	1,459	2,863
Amortization of loan costs	13	0
Stock-based compensation	7,363	5,399
Non-cash lease expense	418	524
Deferred income tax expense (benefit)	13	(599)
Change in fair value of contingent consideration	720	(3,335)
Accretion of investments	(390)	0
Loss on disposal of property and equipment, net	68	18
Loss / (gain) on disposal of assets held for rent, net	218	(96)
Other	(50)	(17)
Change in operating assets and liabilities, net of effects of acquisitions
Accounts receivable, trade, net	3,612	(1,083)
Inventories	(6,425)	(1,855)
Prepaid expenses and other assets	661	(1,213)
Accounts payable	157	(3,231)
Accrued expenses and other current liabilities	371	(1,074)
Warranty liability	583	0
Sales taxes payable	510	1,543
Other	(20)	0
Net cash used in operating activities	(2,712)	(7,924)
Cash flows from investing activities
Purchases of available-for-sale securities	(8,202)	0
Proceeds from sale of available-for-sale securities	524	0
Maturities of available-for-sale securities	14,900	0
Purchases of assets held for rent	(1,001)	(814)
Purchases of property and equipment	(3,295)	(1,456)
Net cash provided by (used in) investing activities	2,926	(2,270)
Cash flows from financing activities
Proceeds from exercise of common stock options	125	257
Fees paid related to issuance of common stock	0	(50)
Other	9	42
Net cash used in financing activities	(562)	(181)
Net decrease in cash, cash equivalents, and restricted cash	(348)	(10,375)
Cash, cash equivalents, and restricted cash – beginning of period	19,473	69,870
Effects of currency translation on cash, cash equivalents, and restricted cash	11	(22)
Cash, cash equivalents, and restricted cash – end of period	19,136	59,473
Non-cash investing and financing activities
Purchase of property and equipment not yet paid	347	13
Equipment acquired under operating leases	880	243
Unrealized gains and losses on available-for-sale securities	(39)	0
Cash interest paid	497	91
Equipment Loans [Member]
Cash flows from financing activities
Payments on loans	(127)	(125)
Financed Insurance Premium [Member]
Cash flows from financing activities
Payments on financed insurance premium	$ (569)	$ (305)

Note 1 - Organization and Signi

Note 1 - Organization and Significant Accounting Policies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Basis of Presentation and Significant Accounting Policies [Text Block]	1. Organization and significant accounting policies Business BioLife Solutions, Inc. (“BioLife”, “us”, “we”, “our”, or the “Company”) is a developer, manufacturer, and supplier of a portfolio of bioproduction tools and services including proprietary biopreservation media, automated thawing devices, cloud-connected shipping containers, ultra-low temperature mechanical freezers, cryogenic and controlled rate freezers, and biological and pharmaceutical materials storage. Our CryoStor® freeze media and HypoThermosol® hypothermic storage media are optimized to preserve cells in the regenerative medicine market. These novel biopreservation media products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death. Our Sexton cell processing product line includes human platelet lysates (“hPL”) for cell expansion, reducing risk and improving downstream performance over fetal bovine serum, human serum, and other chemically defined media, CellSeal® cryogenic vials that are purpose-built rigid containers used in cell and gene therapy (“CGT”) that can be filled manually or with high throughput systems, and automated cell processing machines that bring multiple processes traditionally performed by manual techniques under a higher level of control to protect therapies from loss or contamination. Our ThawSTAR® product line is comprised of a family of automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. These products help administer temperature-sensitive biologic therapies to patients by standardizing the thawing process and reducing the risks of contamination and overheating, which are inherent with the use of traditional water baths. Our cryogenic freezer technology provides for controlled rate freezing and cryogenic storage of biologic materials. Our ultra-low temperature mechanical freezers allow biological materials and vaccines to be stored at temperatures which range from negative 20℃ 86℃. Use of estimates The preparation of financial statements in conformity with generally accepted accounting principles in the United States (“U.S. GAAP”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions by management affect the Company’s net realizable value of inventory, fair value of warrant liability, sales tax liabilities, valuation of market based awards, valuations and purchase price allocations related to investments and business combinations, fair value of marketable debt securities, expected future cash flows including growth rates, discount rates, terminal values and other assumptions and estimates used to evaluate the recoverability of long-lived assets, estimated fair values of intangible assets and goodwill, amortization methods and periods, warranty reserves, certain accrued expenses, stock-based compensation, contingent consideration from business combinations, and provision for income taxes. The Company regularly assesses these estimates; however, actual results could differ materially from these estimates. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and various other assumptions that it believes to be reasonable under the circumstances. Basis of presentation The Unaudited Condensed Consolidated Financial Statements included herein have been prepared by BioLife in accordance with U.S. GAAP and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”), for Quarterly Reports on Form 10 10 X not 10 December 31, 2022 ( The Unaudited Condensed Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiaries, SAVSU Technologies, Inc. (“SAVSU”), Arctic Solutions, Inc. doing business as Custom Biogenic Systems (“CBS”), SciSafe Holdings, Inc. (“SciSafe”), BioLife Solutions B.V, Global Cooling, Inc. doing business as Stirling Ultracold (“Global Cooling” or “GCI”), and Sexton Biotechnologies, Inc. (“Sexton”). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying Unaudited Condensed Consolidated Financial Statements include all adjustments, consisting of only normal, recurring adjustments necessary for a fair presentation of the financial position, results of operations, and cash flows. The results of operations for the interim periods presented are not Foreign currency translation The Company translates items presented on its Unaudited Condensed Consolidated Balance Sheet, Unaudited Condensed Consolidated Statements of Operations, Unaudited Condensed Consolidated Statements of Shareholders’ Equity, and Unaudited Condensed Consolidated Statements of Cash Flows into U.S. dollars. For the Company’s subsidiaries that operate in a local currency functional environment, all assets and liabilities are translated into U.S. dollars using current exchange rates at the balance sheet date; revenue and expenses are translated using average exchange rates in effect during each period. Resulting translation adjustments are reported as a separate component of Accumulated Other Comprehensive Loss in the Unaudited Condensed Consolidated Statements of Shareholders' Equity. Segment reporting The Company views its operations and makes decisions regarding how to allocate resources and manages its business as one one Significant accounting policies There have been no three March 31, 2023, Liquidity and capital resources On March 31, 2023 December 31, 2022, 2022 3. 13: Long-term debt 2022 3. twelve 10 may may not Risks and uncertainties Supply chain considerations Our domestic and international supply chain operations had been affected by the global pandemic of the coronavirus (“COVID- 19” 19 Constraints that had been experienced in the international supply chain for semiconductor chips since 2021 continued to impact our business through the three months ended March 31, 2023. Though our costs to obtain semiconductor components normalized throughout the year ended December 31, 2022 and three months ended March 31, 2023, we were still experiencing constraints in obtaining electrical component parts in a growing macroeconomic trend for manufacturing companies as electrical component parts have maintained high demand. We expect these constraints to improve through diversification of our semiconductor supply chain partnerships. We have sufficient supply for electrical component parts within our operations for the foreseeable future. The Company continues to actively monitor and manage supply chain constraints through alternative sourcing of parts where possible. Continuing or worsening supply chain, labor, and logistics constraints may Concentrations of credit risk and business risk Significant customers are those that represent more than 10% Accounts Receivable Revenue March 31, December 31, Three Months Ended March 31, 2023 2022 2023 2022 Customer A * 15 % * * Customer B * * 14 % 20 % Customer C 12 % 11 % 10 % 11 % * less than 10% Revenue from foreign customers is denominated in United States dollars or euros. The following table represents the Company’s products representing more than 10% Three Months Ended March 31, Product revenue concentration 2023 2022 CryoStor 44 % 35 % 780XLE Freezer 14 % 20 % The following table represents the Company’s total revenue by geographic area (based on the location of the customer): Three Months Ended March 31, Revenue by customers geographic locations 2023 2022 United States 79 % 79 % Europe, Middle East, Africa (EMEA) 18 % 16 % Canada 1 % 1 % Other 2 % 4 % Total revenue 100 % 100 % In the three March 31, 2023, three March 31, 2022, 10% As of March 31, 2023 December 31, 2022, Recent accounting pronouncements As of January 1, 2023, 2016 13, Measurement of Credit Losses on Financial Instruments 326 326, No. 2022 02, Financial Instruments-Credit Losses (Topic 326 2022 02 2022 02 326 326 326 326 30, Financial Instruments Credit Losses Available-for-Sale Debt Securities 326 March 31, 2023, 326 not

Note 2 - Correction of Immateri

Note 2 - Correction of Immaterial Errors	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Error Correction [Text Block]	2. Correction of immaterial errors As reported in our Annual Report as of and for the fiscal year ended December 31, 2022, December 31, 2019 not not not March 31, 2022 The effect of the adjustments to our Unaudited Condensed Consolidated Balance Sheet as of March 31, 2022 March 31, 2022 (In thousands) As reported Adjustment As corrected Prepaid expenses and other current assets $ 4,757 $ 267 $ 5,024 Total current assets 118,701 267 118,968 Total assets 544,012 267 544,279 Accrued expenses and other current liabilities 6,966 (233 ) 6,733 Sales taxes payable - 2,945 2,945 Total current liabilities 35,040 2,712 37,752 Total liabilities 65,492 2,712 68,204 Accumulated deficit (112,086 ) (2,445 ) (114,531 ) Total shareholders’ equity 478,520 (2,445 ) 476,075 Total liabilities and shareholders’ equity 544,012 267 544,279 The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Operations for the quarter ended March 31, 2022 Three Months Ended March 31, 2022 (In thousands, except per share and share data) As reported Adjustment As corrected General and administrative $ 11,196 $ 334 $ 11,530 Total operating expenses 43,853 334 44,187 Operating loss (7,633 ) (334 ) (7,967 ) Interest expense (163 ) (21 ) (184 ) Total other expense, net (32 ) (21 ) (53 ) Loss before income tax benefit (7,665 ) (355 ) (8,020 ) Net loss (7,066 ) (355 ) (7,421 ) Net loss per basic and diluted share (0.17 ) (0.01 ) (0.18 ) The effect of the adjustments to our Unaudited Condensed Consolidated Statements of Cash flows for the quarter ended March 31, 2022 Three Months Ended March 31, 2022 (In thousands) As reported Adjustment As corrected Net loss $ (7,066 ) $ (355 ) $ (7,421 ) Prepaid expenses and other current assets (25 ) (1,188 ) (1,213 ) Sales taxes payable - 1,543 1,543

Note 3 - Fair Value Measurement

Note 3 - Fair Value Measurement	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Fair Value Disclosures [Text Block]	3. Fair value measurement In accordance with FASB ASC Topic 820, 1 2 2 3 820 820 three Level 1 Level 2 1 not Level 3 The fair value of the SciSafe Contingent Consideration Liability was initially valued based on unobservable inputs using a Monte Carlo simulation. These inputs included the estimated amount and timing of projected future revenue, a discount rate of 4.5%, a risk-free rate of approximately 0.20%, asset volatility of 60%, and revenue volatility of 15%. Significant changes in any of those inputs in isolation would result in a significant change in the fair value measurement of the liability. Generally, changes used in the assumptions for projected future revenue and revenue volatility would be accompanied by a directionally similar change in the fair value measurement. Conversely, changes in the discount rate would be accompanied by a directionally opposite change in the related fair value measurement. However, due to the contingent consideration having a maximum payout amount, changes in these assumptions would not March 31, 2023, March 31, 2023 December 31, 2022 three March 31, 2023 2022, December 31, 2022, second three March 31, 2023. There were no three March 31, 2023 not The following tables set forth the Company’s financial assets and liabilities measured at fair value on a recurring basis as of March 31, 2023 December 31, 2022, three (In thousands) As of March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 14,021 $ - $ - $ 14,021 Available-for-sale securities: U.S. government securities 9,377 - - 9,377 Corporate debt securities - 24,663 - 24,663 Other debt securities - 3,759 - 3,759 Total $ 23,398 $ 28,422 $ - $ 51,820 Liabilities: Contingent consideration - business combinations - - 5,176 5,176 Debt - 24,942 - 24,942 Total $ - $ 24,942 $ 5,176 $ 30,118 As of December 31, 2022 Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total $ 26,467 $ 29,541 $ - $ 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063 There have been no The following table presents the changes in fair value of contingent consideration liabilities which are measured using Level 3 Three Months Ended March 31, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 4,456 $ 10,027 Change in fair value recognized in net loss 720 (3,335 ) Ending balance $ 5,176 $ 6,692

Note 4 - Investments

Note 4 - Investments	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Investment [Text Block]	4. Investments Available-for-sale securities The Company’s portfolio of available-for-sale marketable securities consists of the following: March 31, 2023 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 9,386 $ - $ 9 $ 9,377 Corporate debt securities 24,663 7 7 24,663 Other debt securities 1,743 - 3 1,740 Total short-term 35,792 7 19 35,780 Available-for-sale securities, long-term Other debt securities 2,018 2 1 2,019 Total marketable securities $ 37,810 $ 9 $ 20 $ 37,799 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 35,792 $ 35,780 Due after one year through five years 2,018 2,019 Total $ 37,810 $ 37,799 Equity investments The Company periodically invests in non-marketable equity securities of private companies without a readily determinable fair value to promote business and strategic objectives. These securities included Series A- 1 2 March 31, 2023 December 31, 2022, March 31, 2023 December 31, 2022.

Note 5 - Inventories

Note 5 - Inventories	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Inventory Disclosure [Text Block]	5. Inventories Inventories consists of the following as of March 31, 2023 December 31, 2022: (In thousands) 2023 2022 Raw materials $ 23,682 $ 20,950 Work in progress 6,934 5,680 Finished goods 10,713 8,274 Total $ 41,329 $ 34,904

Note 6 - Leases

Note 6 - Leases	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Lessee, Leases [Text Block]	6. Leases The Company has various operating lease agreements for office space, warehouses, manufacturing, and production locations as well as vehicles and other equipment. Our real estate leases have remaining lease terms of one ten not one five one five Our financing leases relate to research equipment, machinery, and other equipment. The table below presents certain information related to the weighted average discount rate and weighted average remaining lease term for the Company’s leases as of March 31, 2023 December 31, 2022: March 31, December 31, (In thousands) 2023 2022 Weighted average discount rate - operating leases 4.3 % 4.2 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 6.9 7.2 Weighted average remaining lease term in years - finance leases 1.8 2.0 The components of lease expense for the three March 31, 2023 2022 Three Months Ended March 31, (In thousands) 2023 2022 Operating lease costs $ 897 $ 913 Short-term lease costs 402 565 Total operating lease costs 1,299 1,478 Variable lease costs 259 305 Total lease costs $ 1,558 $ 1,783 Maturities of our lease liabilities as of March 31, 2023 (In thousands) Operating Leases Financing Leases 2023 (9 months remaining) $ 2,690 $ 128 2024 3,398 101 2025 2,954 38 2026 2,533 2 2027 2,280 - Thereafter 6,938 - Total lease payments 20,793 269 Less: interest (2,773 ) (13 ) Total present value of lease liabilities $ 18,020 $ 256

Note 7 - Assets Held for Rent

Note 7 - Assets Held for Rent	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Assets Held For Rent [Text Block]	7. Assets held for rent Assets held for rent consist of the following as of March 31, 2023 December 31, 2022: (In thousands) 2023 2022 Shippers placed in service $ 8,132 $ 7,671 Fixed assets held for rent 4,686 4,686 Accumulated depreciation (5,451 ) (4,952 ) Subtotal 7,367 7,405 Shippers and related components in production 1,638 1,659 Total $ 9,005 $ 9,064 Shippers and related components in production include shippers complete and ready to be deployed and placed in service upon a customer order, shippers in the process of being assembled, and components available to build shippers. We recognized $843,000 and $896,000 in depreciation expense related to assets held for rent during the three March 31, 2023 2022,

Note 8 - Property and Equipment

Note 8 - Property and Equipment	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	8. Property and equipment Property and equipment consist of the following as of March 31, 2023 December 31, 2022: March 31, December 31, (In thousands) 2023 2022 Property and equipment Leasehold improvements $ 5,110 $ 5,249 Furniture and computer equipment 1,954 1,908 Manufacturing and other equipment 21,278 20,557 Construction in-progress 7,381 5,095 Subtotal 35,723 32,809 Less: Accumulated depreciation (9,623 ) (9,171 ) Property and equipment, net $ 26,100 $ 23,638 Depreciation expense for property and equipment was $878,000 and $757,000 for the three March 31, 2023 2022,

Note 9 - Goodwill and Intangibl

Note 9 - Goodwill and Intangible Assets	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Goodwill and Intangible Assets Disclosure [Text Block]	9. Goodwill and intangible assets Goodwill Goodwill represents the difference between the purchase price and the estimated fair value of identifiable assets acquired and liabilities assumed. Goodwill acquired in a business combination is determined to have an indefinite useful life and is not 350. Intangible assets Intangible assets, net consisted of the following as of March 31, 2023 December 31, 2022: (In thousands, except weighted average useful life) March 31, 2023 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (4,446 ) $ 6,842 9.1 Tradenames 13,731 (4,556 ) 9,175 12.6 Technology - acquired 27,892 (13,528 ) 14,364 4.6 Non-compete agreements 1,187 (939 ) 248 1.8 Total intangible assets $ 54,098 $ (23,469 ) $ 30,629 8.0 (In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (3,993 ) $ 7,295 9.3 Tradenames 13,731 (4,323 ) 9,408 12.8 Technology - acquired 27,892 (12,796 ) 15,096 4.9 Non-compete agreements 1,187 (898 ) 289 2.0 Total intangible assets $ 54,098 $ (22,010 ) $ 32,088 8.2 Amortization expense for definite-lived intangible assets was $1.5 million and $2.9 million for the three March 31, 2023 2022, March 31, 2023, (In thousands) Amortization For the Years Ending December 31, Expense 2023 (9 months remaining) $ 3,972 2024 4,607 2025 4,435 2026 4,137 2027 3,383 Thereafter 10,095 Total $ 30,629

Note 10 - Accrued Expenses and

Note 10 - Accrued Expenses and Other Current Liabilities	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]	10. Accrued expenses and other current liabilities Accrued expenses and other current liabilities consist of the following as of March 31, 2023 December 31, 2022: March 31, December 31, (In thousands) 2023 2022 Accrued compensation $ 5,306 $ 5,080 Accrued expenses 3,825 3,128 Deferred revenue, current 422 548 Accrued taxes 1,148 975 Other - 51 Total accrued expenses and other current liabilities $ 10,701 $ 9,782

Note 11 - Warranty Reserve Liab

Note 11 - Warranty Reserve Liability	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Product Warranty Disclosure [Text Block]	11. Warranty reserve liability The Company reserves estimated exposures on known claims, as well as anticipated claims, for product warranty and rework cost, based on historical product liability claims. Claim costs are deducted from the accrual when paid. Factors that could have an impact on the warranty accrual in any given period include the following: changes in manufacturing quality, changes in product costs, changes in product mix and any significant changes in sales volume. A rollforward of our warranty liability is as follows: Three Months Ended March 31, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 8,312 $ 9,398 Provision for warranties (1) 1,891 1,419 Settlements of warranty claims (1) (1,308 ) (1,641 ) Ending Balance $ 8,895 $ 9,176 ( 1 Both the Provision for warranties and Settlements of warranty claims balances during the three March 31, 2022

Note 12 - Commitments and Conti

Note 12 - Commitments and Contingencies	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and contingencies Employment agreements We have employment agreements with certain key employees. None may Litigation From time to time, the Company is subject to various legal proceedings that arise in the ordinary course of business, none may not Indemnification As permitted under Delaware law and in accordance with the Company’s bylaws, the Company is required to indemnify its officers and directors for certain errors and occurrences while the officer or director is or was serving in such capacity. The Company is also party to indemnification agreements with its directors. The Company believes the fair value of the indemnification rights and agreements is minimal. Accordingly, the Company has not March 31, 2023. Non-income related taxes Companies are required to collect and remit sales tax from certain customers if the company is determined to have nexus in a particular state. Upon the determination of nexus, which varies by state, companies are additionally required to maintain detailed record of specific product and customer information within each jurisdiction in which it has established nexus to appropriately determine their sales tax liability, requiring technical knowledge of each jurisdiction’s tax case law. During the year ended December 31, 2022, 2019 2022 March 31, 2023 December 31, 2022, 2019 2022, March 31, 2023 December 31, 2022,

Note 13 - Long-term Debt

Note 13 - Long-term Debt	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Long-Term Debt [Text Block]	13. Long-term debt 2022 3 On September 20, 2022, June 1, 2026. June 30, 2023, June 2024, June 2025. 2022 3 2022 3 Long-term debt consisted of the following as of March 31, 2023 December 31, 2022: March 31, December 31, (In thousands) Maturity Date Interest Rate 2023 2022 2022 term loan 2 Various 4.0 % 2,896 2,896 2022 term loan 3 Jun-26 6.8 % 20,000 20,000 Insurance premium financing Apr-23 5.0 % 505 1,074 Freezer equipment loan Dec-25 5.7 % 430 466 Manufacturing equipment loans Oct-25 5.7 % 243 266 Freezer installation loan Various 6.3 % 1,012 1,078 Other loans Various Various 5 6 Total debt, excluding unamortized debt issuance costs 25,091 25,786 Less: unamortized debt issuance costs (149 ) (179 ) Total debt 24,942 25,607 Less: current portion (1,250 ) (1,814 ) Total long-term debt $ 23,692 $ 23,793 2022 3 2022 2 2022 3. As of March 31, 2023, five (In thousands) Amount 2023 (9 months remaining) $ 1,135 2024 5,481 2025 10,511 2026 5,219 2027 2,596 Thereafter - Total debt 24,942

Note 14 - Revenue

Note 14 - Revenue	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Revenue from Contract with Customer [Text Block]	14. Revenue To determine revenue recognition for contractual arrangements that we determine are within the scope of FASB Topic 606, Revenue from Contracts with Customers five five may not 30 90 March 31, 2023 December 31, 2022, three March 31, 2023, The Company primarily recognizes product revenues, service revenues, and rental revenues. Product revenues are generated from the sale of cell processing tools, freezers, thawing devices, and cold chain products. We recognize product revenue, including shipping and handling charges billed to customers, at a point in time when we transfer control of our products to our customers, which is upon shipment for substantially all transactions. Shipping and handling costs are classified as part of cost of product revenue in the Consolidated Statements of Operations. Service revenue is generated from the storage of biological and pharmaceutical materials. We recognize service revenue over time as services are performed or ratably over the contract term. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price utilizing the expected value method or the most likely amount method, depending on the facts and circumstances relative to the contract. When determining the transaction price of a contract, an adjustment is made if payment from a customer occurs either significantly before or significantly after performance, resulting in a significant financing component. Applying the practical expedient in ASC Topic 606, not one None three March 31, 2023. The Company also generates revenue from the leasing of our property, plant, and equipment, operating right-of-use assets, and evo cold chain systems within its storage and storage services product line to customers pursuant to service contracts or rental arrangements entered into with the customer. Revenue from these arrangements is not 606 842, Lease The Company enters into various customer service agreements (collectively, “Service Contracts”) with customers to provide biological and pharmaceutical storage services. In certain of these Service Contracts, the property, plant, and equipment or operating right-of-use assets used to store the customer product are used only for the benefit of one may not The Company has assessed its Service Contracts and concluded that certain of the contracts for the storage of customer products met the criteria to be considered a leasing arrangement (“Embedded Leases”), with the Company as the lessor. The specific Service Contracts that met the criteria were those that provided a single customer with the ability to substantially direct the use of the Company’s property, plant, and equipment or operating right-of-use assets. Applying the practical expedient from ASC Topic 842, None None Embedded Leases may 842 Total bioproduction tools and services revenue for the three March 31, 2023 2022 Three Months Ended March 31, (In thousands, except percentages) 2023 2022 Product revenue Freezer and thaw $ 12,381 $ 15,335 Cell processing 18,993 14,899 Storage and storage services 219 154 Service revenue Storage and storage services 3,825 3,090 Freezer and thaw 646 - Rental revenue Storage and storage services 1,639 2,742 Total revenue $ 37,703 $ 36,220 The following table includes estimated rental revenue expected to be recognized in the future related to embedded leases as well as estimated service revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied as of the end of the reporting periods. The Company is electing not one 2014 09, Revenue from Contracts with Customers not one March 31, 2023. The balances in the table below are partially based on judgments involved in estimating future orders from customers pursuant to their respective contracts: (In thousands) 2023 (9 months remaining) 2024 Total Rental revenue $ 2,700 $ 900 $ 3,600 Service revenue $ 190 $ 10 $ 200

Note 15 - Stock-based Compensat

Note 15 - Stock-based Compensation	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Share-Based Payment Arrangement [Text Block]	15. Stock-based compensation Service vesting-based stock options The following is a summary of service vesting-based stock option activity for the March 31, 2023, March 31, 2023: Three Months Ended March 31, 2023 Options Wtd. Avg. Exercise Price Outstanding as of beginning of year 456,293 $ 2.16 Exercised (80,938 ) 2.06 Outstanding as of March 31, 2023 375,355 $ 2.18 Stock options exercisable as of March 31, 2023 375,355 $ 2.18 As of March 31, 2023, March 31, 2023. three March 31, 2023 2022, three March 31, 2023. March 31, 2023 March 31, 2023. Restricted stock Service vesting-based restricted stock The following is a summary of service vesting-based restricted stock activity for the three March 31, 2023, March 31, 2023: Three Months Ended March 31, 2023 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,879,215 $ 28.94 Granted 414,601 17.67 Vested (346,184 ) 27.51 Forfeited (70,725 ) 29.67 Non-vested as of March 31, 2023 1,876,907 $ 26.69 The aggregate fair value of the service vesting-based awards granted was $7.3 million and $7.9 million during the three March 31, 2023 2022, three March 31, 2023 2022, We recognized stock compensation expense related to service vesting-based awards of $6.1 million and $4.8 million during the three March 31, 2023 2022, March 31, 2023, Market-based restricted stock The following is a summary of market-based restricted stock activity under our stock option plan for the three March 31, 2023 March 31, 2023: Three Months Ended March 31, 2023 Shares Wtd. Avg. Grant Outstanding as of beginning of year 271,044 $ 30.64 Granted 268,738 24.23 Vested (30,616 ) 51.65 Non-vested as of March 31, 2023 509,166 $ 26.00 On February 8, 2021, March 31, 2023, January 1, 2021 December 31, 2022 20 0% December 31, 2022. On February 24, 2022, January 1, 2022 December 31, 2023 20 0% December 31, 2023. On January 8, 2023, January 1, 2023 December 31, 2024 20 78%, 0% 0% December 31, 2024. We recognized stock compensation expense of $1.3 three March 31, 2023, three March 31, 2022. March 31, 2023, The aggregate fair value of the market-based awards granted was $6.5 million during the three March 31, 2023, three March 31, 2022. three March 31, 2023, three March 31, 2022. Total stock compensation expense We recorded total stock compensation expense for the three March 31, 2023 2022, Three Months Ended March 31, (In thousands) 2023 2022 Cost of revenue $ 1,631 $ 1,007 General and administrative costs 3,293 3,010 Sales and marketing costs 1,256 705 Research and development costs 1,183 677 Total $ 7,363 $ 5,399

Note 16 - Income Taxes

Note 16 - Income Taxes	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Income Tax Disclosure [Text Block]	16. Income taxes The Company accounts for income taxes under ASC Topic 740 The Company’s tax provision for interim periods is determined using an estimate of the annual effective income tax rate, adjusted for discrete items, if any, that occur in the relevant period. The income tax expense of $92,000 for the three March 31, 2023 $92,000 The Company’s US projected effective income tax rate without discrete items was negative 1.1%, which is lower than the US federal statutory rate of 21% primarily due to the increase in the valuation allowance on US deferred tax assets and non-deductible executive compensation offset by state tax benefits and research tax credits. Realization of deferred tax assets is dependent upon the generation of future taxable income, the timing and amount of which are uncertain. In determining the need for a valuation allowance, the Company’s management evaluates both positive and negative evidence when concluding whether it is more likely than not

Note 17 - Net (Loss) Income Per

Note 17 - Net (Loss) Income Per Common Share	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Earnings Per Share [Text Block]	17. Net loss per common share The Company considers its unexercised warrants and unvested restricted shares, which contain non-forfeitable rights to dividends, participating securities, and includes such participating securities in its computation of earnings per share pursuant to the two two two The following table presents computations of basic and diluted earnings per share under the two Three Months Ended March 31, (In thousands, except share and earnings per share data) 2023 2022 Basic earnings (loss) per common share Numerator: Net loss $ (13,714 ) $ (7,421 ) Net loss allocated to common shareholders (13,714 ) (7,421 ) Denominator: Weighted-average common shares issued and outstanding 43,027,612 42,014,055 Basic loss earnings per common share $ (0.32 ) $ (0.18 ) The following table sets forth the number of weighted-average common shares excluded from the computation of diluted loss per share, as their inclusion would have been anti-dilutive: Three Months Ended March 31, 2023 2022 Stock options and restricted stock awards 3,153,029 2,094,863 Total 3,153,029 2,094,863

Note 18 - Employee Benefit Plan

Note 18 - Employee Benefit Plan	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Defined Contribution Plan [Text Block]	18. Employee benefit plan The Company sponsors 401 may three March 31, 2023 2022,

Note 19 - Subsequent Events

Note 19 - Subsequent Events	3 Months Ended
	Mar. 31, 2023
Notes to Financial Statements
Subsequent Events [Text Block]	19. Subsequent events The Company has evaluated events subsequent to March 31, 2023 no

Note 1 - Organization and Sig_2

Note 1 - Organization and Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	Accounts Receivable Revenue March 31, December 31, Three Months Ended March 31, 2023 2022 2023 2022 Customer A * 15 % * * Customer B * * 14 % 20 % Customer C 12 % 11 % 10 % 11 %
Revenue from External Customers by Products and Services [Table Text Block]	Three Months Ended March 31, Product revenue concentration 2023 2022 CryoStor 44 % 35 % 780XLE Freezer 14 % 20 % Three Months Ended March 31, Revenue by customers geographic locations 2023 2022 United States 79 % 79 % Europe, Middle East, Africa (EMEA) 18 % 16 % Canada 1 % 1 % Other 2 % 4 % Total revenue 100 % 100 %

Note 2 - Correction of Immate_2

Note 2 - Correction of Immaterial Errors (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]	March 31, 2022 (In thousands) As reported Adjustment As corrected Prepaid expenses and other current assets $ 4,757 $ 267 $ 5,024 Total current assets 118,701 267 118,968 Total assets 544,012 267 544,279 Accrued expenses and other current liabilities 6,966 (233 ) 6,733 Sales taxes payable - 2,945 2,945 Total current liabilities 35,040 2,712 37,752 Total liabilities 65,492 2,712 68,204 Accumulated deficit (112,086 ) (2,445 ) (114,531 ) Total shareholders’ equity 478,520 (2,445 ) 476,075 Total liabilities and shareholders’ equity 544,012 267 544,279 Three Months Ended March 31, 2022 (In thousands, except per share and share data) As reported Adjustment As corrected General and administrative $ 11,196 $ 334 $ 11,530 Total operating expenses 43,853 334 44,187 Operating loss (7,633 ) (334 ) (7,967 ) Interest expense (163 ) (21 ) (184 ) Total other expense, net (32 ) (21 ) (53 ) Loss before income tax benefit (7,665 ) (355 ) (8,020 ) Net loss (7,066 ) (355 ) (7,421 ) Net loss per basic and diluted share (0.17 ) (0.01 ) (0.18 ) Three Months Ended March 31, 2022 (In thousands) As reported Adjustment As corrected Net loss $ (7,066 ) $ (355 ) $ (7,421 ) Prepaid expenses and other current assets (25 ) (1,188 ) (1,213 ) Sales taxes payable - 1,543 1,543

Note 3 - Fair Value Measureme_2

Note 3 - Fair Value Measurement (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	As of March 31, 2023 Level 1 Level 2 Level 3 Total Assets: Cash equivalents: Money market accounts $ 14,021 $ - $ - $ 14,021 Available-for-sale securities: U.S. government securities 9,377 - - 9,377 Corporate debt securities - 24,663 - 24,663 Other debt securities - 3,759 - 3,759 Total $ 23,398 $ 28,422 $ - $ 51,820 Liabilities: Contingent consideration - business combinations - - 5,176 5,176 Debt - 24,942 - 24,942 Total $ - $ 24,942 $ 5,176 $ 30,118 As of December 31, 2022 Assets: Cash equivalents: Money market accounts $ 11,416 $ - $ - $ 11,416 Available-for-sale securities: U.S. government securities 15,051 - - 15,051 Corporate debt securities - 26,047 - 26,047 Other debt securities - 3,494 - 3,494 Total $ 26,467 $ 29,541 $ - $ 56,008 Liabilities: Contingent consideration - business combinations - - 4,456 4,456 Debt - 25,607 - 25,607 Total $ - $ 25,607 $ 4,456 $ 30,063
Contingent Consideration Liabilities [Member]
Notes Tables
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Three Months Ended March 31, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 4,456 $ 10,027 Change in fair value recognized in net loss 720 (3,335 ) Ending balance $ 5,176 $ 6,692

Note 4 - Investments (Tables)

Note 4 - Investments (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Debt Securities, Available-for-Sale [Table Text Block]	March 31, 2023 Amortized Gross unrealized Estimated (In thousands) Cost Gains Losses Fair Value Available-for-sale securities, current portion U.S. government securities $ 9,386 $ - $ 9 $ 9,377 Corporate debt securities 24,663 7 7 24,663 Other debt securities 1,743 - 3 1,740 Total short-term 35,792 7 19 35,780 Available-for-sale securities, long-term Other debt securities 2,018 2 1 2,019 Total marketable securities $ 37,810 $ 9 $ 20 $ 37,799 Amortized Estimated (In thousands) Cost Fair Value Due in one year or less $ 35,792 $ 35,780 Due after one year through five years 2,018 2,019 Total $ 37,810 $ 37,799

Note 5 - Inventories (Tables)

Note 5 - Inventories (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Inventory, Current [Table Text Block]	(In thousands) 2023 2022 Raw materials $ 23,682 $ 20,950 Work in progress 6,934 5,680 Finished goods 10,713 8,274 Total $ 41,329 $ 34,904

Note 6 - Leases (Tables)

Note 6 - Leases (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Lessee, Operating and Finance Lease Term And Discount Rate [Table Text Block]	March 31, December 31, (In thousands) 2023 2022 Weighted average discount rate - operating leases 4.3 % 4.2 % Weighted average discount rate - finance leases 6.1 % 6.1 % Weighted average remaining lease term in years - operating leases 6.9 7.2 Weighted average remaining lease term in years - finance leases 1.8 2.0
Lease, Cost [Table Text Block]	Three Months Ended March 31, (In thousands) 2023 2022 Operating lease costs $ 897 $ 913 Short-term lease costs 402 565 Total operating lease costs 1,299 1,478 Variable lease costs 259 305 Total lease costs $ 1,558 $ 1,783
Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]	(In thousands) Operating Leases Financing Leases 2023 (9 months remaining) $ 2,690 $ 128 2024 3,398 101 2025 2,954 38 2026 2,533 2 2027 2,280 - Thereafter 6,938 - Total lease payments 20,793 269 Less: interest (2,773 ) (13 ) Total present value of lease liabilities $ 18,020 $ 256

Note 7 - Assets Held for Rent (

Note 7 - Assets Held for Rent (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Scheduleof Assets Held for Rent [Table Text Block]	(In thousands) 2023 2022 Shippers placed in service $ 8,132 $ 7,671 Fixed assets held for rent 4,686 4,686 Accumulated depreciation (5,451 ) (4,952 ) Subtotal 7,367 7,405 Shippers and related components in production 1,638 1,659 Total $ 9,005 $ 9,064

Note 8 - Property and Equipme_2

Note 8 - Property and Equipment (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Property, Plant and Equipment [Table Text Block]	March 31, December 31, (In thousands) 2023 2022 Property and equipment Leasehold improvements $ 5,110 $ 5,249 Furniture and computer equipment 1,954 1,908 Manufacturing and other equipment 21,278 20,557 Construction in-progress 7,381 5,095 Subtotal 35,723 32,809 Less: Accumulated depreciation (9,623 ) (9,171 ) Property and equipment, net $ 26,100 $ 23,638

Note 9 - Goodwill and Intangi_2

Note 9 - Goodwill and Intangible Assets (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	(In thousands, except weighted average useful life) March 31, 2023 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (4,446 ) $ 6,842 9.1 Tradenames 13,731 (4,556 ) 9,175 12.6 Technology - acquired 27,892 (13,528 ) 14,364 4.6 Non-compete agreements 1,187 (939 ) 248 1.8 Total intangible assets $ 54,098 $ (23,469 ) $ 30,629 8.0 (In thousands, except weighted average useful life) December 31, 2022 Intangible assets: Gross Carrying Value Accumulated Amortization Net Carrying Value Weighted Average Useful Life (in years) Customer Relationships $ 11,288 $ (3,993 ) $ 7,295 9.3 Tradenames 13,731 (4,323 ) 9,408 12.8 Technology - acquired 27,892 (12,796 ) 15,096 4.9 Non-compete agreements 1,187 (898 ) 289 2.0 Total intangible assets $ 54,098 $ (22,010 ) $ 32,088 8.2
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	(In thousands) Amortization For the Years Ending December 31, Expense 2023 (9 months remaining) $ 3,972 2024 4,607 2025 4,435 2026 4,137 2027 3,383 Thereafter 10,095 Total $ 30,629

Note 10 - Accrued Expenses an_2

Note 10 - Accrued Expenses and Other Current Liabilities (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Other Current Liabilities [Table Text Block]	March 31, December 31, (In thousands) 2023 2022 Accrued compensation $ 5,306 $ 5,080 Accrued expenses 3,825 3,128 Deferred revenue, current 422 548 Accrued taxes 1,148 975 Other - 51 Total accrued expenses and other current liabilities $ 10,701 $ 9,782

Note 11 - Warranty Reserve Li_2

Note 11 - Warranty Reserve Liability (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Product Warranty Liability [Table Text Block]	Three Months Ended March 31, (In thousands) 2023 2022 Beginning balance as of December 31, 2022 and 2021 $ 8,312 $ 9,398 Provision for warranties (1) 1,891 1,419 Settlements of warranty claims (1) (1,308 ) (1,641 ) Ending Balance $ 8,895 $ 9,176

Note 13 - Long-term Debt (Table

Note 13 - Long-term Debt (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Debt [Table Text Block]	March 31, December 31, (In thousands) Maturity Date Interest Rate 2023 2022 2022 term loan 2 Various 4.0 % 2,896 2,896 2022 term loan 3 Jun-26 6.8 % 20,000 20,000 Insurance premium financing Apr-23 5.0 % 505 1,074 Freezer equipment loan Dec-25 5.7 % 430 466 Manufacturing equipment loans Oct-25 5.7 % 243 266 Freezer installation loan Various 6.3 % 1,012 1,078 Other loans Various Various 5 6 Total debt, excluding unamortized debt issuance costs 25,091 25,786 Less: unamortized debt issuance costs (149 ) (179 ) Total debt 24,942 25,607 Less: current portion (1,250 ) (1,814 ) Total long-term debt $ 23,692 $ 23,793
Schedule of Maturities of Long-Term Debt [Table Text Block]	(In thousands) Amount 2023 (9 months remaining) $ 1,135 2024 5,481 2025 10,511 2026 5,219 2027 2,596 Thereafter - Total debt 24,942

Note 14 - Revenue (Tables)

Note 14 - Revenue (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Revenues By Product Line [Table Text Block]	Three Months Ended March 31, (In thousands, except percentages) 2023 2022 Product revenue Freezer and thaw $ 12,381 $ 15,335 Cell processing 18,993 14,899 Storage and storage services 219 154 Service revenue Storage and storage services 3,825 3,090 Freezer and thaw 646 - Rental revenue Storage and storage services 1,639 2,742 Total revenue $ 37,703 $ 36,220
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]	(In thousands) 2023 (9 months remaining) 2024 Total Rental revenue $ 2,700 $ 900 $ 3,600 Service revenue $ 190 $ 10 $ 200

Note 15 - Stock-based Compens_2

Note 15 - Stock-based Compensation (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Three Months Ended March 31, 2023 Options Wtd. Avg. Exercise Price Outstanding as of beginning of year 456,293 $ 2.16 Exercised (80,938 ) 2.06 Outstanding as of March 31, 2023 375,355 $ 2.18 Stock options exercisable as of March 31, 2023 375,355 $ 2.18
Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]	Three Months Ended March 31, 2023 Shares Wtd. Avg. Grant Date Fair Value Outstanding as of beginning of year 1,879,215 $ 28.94 Granted 414,601 17.67 Vested (346,184 ) 27.51 Forfeited (70,725 ) 29.67 Non-vested as of March 31, 2023 1,876,907 $ 26.69 Three Months Ended March 31, 2023 Shares Wtd. Avg. Grant Outstanding as of beginning of year 271,044 $ 30.64 Granted 268,738 24.23 Vested (30,616 ) 51.65 Non-vested as of March 31, 2023 509,166 $ 26.00
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]	Three Months Ended March 31, (In thousands) 2023 2022 Cost of revenue $ 1,631 $ 1,007 General and administrative costs 3,293 3,010 Sales and marketing costs 1,256 705 Research and development costs 1,183 677 Total $ 7,363 $ 5,399

Note 17 - Net (Loss) Income P_2

Note 17 - Net (Loss) Income Per Common Share (Tables)	3 Months Ended
	Mar. 31, 2023
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Three Months Ended March 31, (In thousands, except share and earnings per share data) 2023 2022 Basic earnings (loss) per common share Numerator: Net loss $ (13,714 ) $ (7,421 ) Net loss allocated to common shareholders (13,714 ) (7,421 ) Denominator: Weighted-average common shares issued and outstanding 43,027,612 42,014,055 Basic loss earnings per common share $ (0.32 ) $ (0.18 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Three Months Ended March 31, 2023 2022 Stock options and restricted stock awards 3,153,029 2,094,863 Total 3,153,029 2,094,863

Note 1 - Organization and Sig_3

Note 1 - Organization and Significant Accounting Policies (Details Textual)	3 Months Ended		12 Months Ended
	Mar. 31, 2023 USD ($)	Mar. 31, 2022	Dec. 31, 2022 USD ($)	Sep. 20, 2022 USD ($)
Cash, Cash Equivalents, and Short-Term Investments	$ 56,900,000		$ 64,100,000
Supplier Concentration Risk [Member] | Supply Purchase [Member]
Number of Suppliers	1	0
Supplier Concentration Risk [Member] | Supply Purchase [Member] | One Supplier [Member]
Concentration Risk, Percentage	15%
Supplier Concentration Risk [Member] | Accounts Payable [Member]
Number of Suppliers	1		1
Supplier Concentration Risk [Member] | Accounts Payable [Member] | One Supplier [Member]
Concentration Risk, Percentage	22%		23%
The 2022 Term Loan 3 [Member]
Debt Instrument, Maximum Borrowing Capacity at Closing	$ 30,000,000			$ 30,000,000

Note 1 - Organization and Sig_4

Note 1 - Organization and Significant Accounting Policies - Significant Customers (Details) - Customer Concentration Risk [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts Receivable [Member] | Customer A [Member]
Concentration by customer		15%
Accounts Receivable [Member] | Customer C [Member]
Concentration by customer	12%	11%
Revenue Benchmark [Member] | Customer B [Member]
Concentration by customer	14%	20%
Revenue Benchmark [Member] | Customer C [Member]
Concentration by customer	10%	11%

Note 1 - Organization and Sig_5

Note 1 - Organization and Significant Accounting Policies - Concentrations Risk by Geographic Locations (Details) - Revenue Benchmark [Member]	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Product Concentration Risk [Member] | CryoStor Products [Member]
Revenue	44%	35%
Product Concentration Risk [Member] | 780XLE Freezer Line [Member]
Revenue	14%	20%
Geographic Concentration Risk [Member] | UNITED STATES
Revenue	79%	79%
Geographic Concentration Risk [Member] | EMEA [Member]
Revenue	18%	16%
Geographic Concentration Risk [Member] | CANADA
Revenue	1%	1%
Geographic Concentration Risk [Member] | Geographic, Other [Member]
Revenue	2%	4%
Geographic Concentration Risk [Member] | All Location [Member]
Revenue	100%	100%

Note 2 - Correction of Immate_3

Note 2 - Correction of Immaterial Errors - Revisions to Financial Statements (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Dec. 31, 2021
Prepaid expenses and other current assets	$ 6,201	$ 5,024	$ 6,879
Total current assets	132,789	118,968	138,452
Total assets	446,470	544,279	450,229
Accrued expenses and other current liabilities	10,701	6,733	9,782
Sales taxes payable	4,585	2,945	4,151
Total current liabilities	47,319	37,752	44,582
Total liabilities	88,363	68,204	86,041
Accumulated deficit	(260,629)	(114,531)	(246,915)
Total shareholders’ equity	358,107	476,075	364,188	$ 478,047
Total liabilities and shareholders’ equity	446,470	544,279	$ 450,229
General and administrative	14,842	11,530
Total operating expenses	51,308	44,187
Operating loss	(13,605)	(7,967)
Interest (expense) income, net		(184)
Total other expense, net	(17)	(53)
Loss before income tax benefit	(13,622)	(8,020)
Net (loss) income	$ (13,714)	$ (7,421)
Net loss per basic and diluted share (in dollars per share)	$ (0.32)	$ (0.18)
Net (loss) income	$ (13,714)	$ (7,421)
Prepaid expenses and other current assets	661	(1,213)
Sales taxes payable	$ 510	1,543
Previously Reported [Member]
Prepaid expenses and other current assets		4,757
Total current assets		118,701
Total assets		544,012
Accrued expenses and other current liabilities		6,966
Sales taxes payable		0
Total current liabilities		35,040
Total liabilities		65,492
Accumulated deficit		(112,086)
Total shareholders’ equity		478,520
Total liabilities and shareholders’ equity		544,012
General and administrative		11,196
Total operating expenses		43,853
Operating loss		(7,633)
Interest (expense) income, net		(163)
Total other expense, net		(32)
Loss before income tax benefit		(7,665)
Net (loss) income		$ (7,066)
Net loss per basic and diluted share (in dollars per share)		$ (0.17)
Net (loss) income		$ (7,066)
Prepaid expenses and other current assets		(25)
Sales taxes payable		0
Revision of Prior Period, Adjustment [Member]
Prepaid expenses and other current assets		267
Total current assets		267
Total assets		267
Accrued expenses and other current liabilities		(233)
Sales taxes payable		2,945
Total current liabilities		2,712
Total liabilities		2,712
Accumulated deficit		(2,445)
Total shareholders’ equity		(2,445)
Total liabilities and shareholders’ equity		267
General and administrative		334
Total operating expenses		334
Operating loss		(334)
Interest (expense) income, net		(21)
Total other expense, net		(21)
Loss before income tax benefit		(355)
Net (loss) income		$ (355)
Net loss per basic and diluted share (in dollars per share)		$ (0.01)
Net (loss) income		$ (355)
Prepaid expenses and other current assets		(1,188)
Sales taxes payable		$ 1,543

Note 3 - Fair Value Measureme_3

Note 3 - Fair Value Measurement (Details Textual)		3 Months Ended
	Apr. 01, 2023 shares	Mar. 31, 2023 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)	Oct. 01, 2020 USD ($)
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ 720,000	$ (3,335,000)
Shares Issued As Payment for Contingent Consideration Liability [Member] | Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares) | shares	116,973
SciSafe Holdings, Inc [Member]
Business Combination, Contingent Consideration, Liability, Total		5,000,000		$ 4,300,000	$ 3,700,000
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability		$ 720,000	$ (3,300,000)
SciSafe Holdings, Inc [Member] | Measurement Input, Discount Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.130			0.045
SciSafe Holdings, Inc [Member] | Measurement Input, Risk Free Interest Rate [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.044			0.0020
SciSafe Holdings, Inc [Member] | Measurement Input, Asset Price Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.71			0.60
SciSafe Holdings, Inc [Member] | Measurement Input, Revenue Volatility [Member]
Business Combination, Contingent Consideration, Liability, Measurement Input		0.31			0.15

Note 3 - Fair Value Measureme_4

Note 3 - Fair Value Measurement - Financial Assets and Liabilities on Recurring Basis (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Marketable debt securities	$ 37,799
Fair Value, Recurring [Member]
Assets	51,820	$ 56,008
Contingent consideration - business combinations	5,176	4,456
Debt	24,942	25,607
Liabilities	30,118	30,063
Fair Value, Recurring [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	9,377	15,051
Fair Value, Recurring [Member] | Other Debt Obligations [Member]
Marketable debt securities	3,759	3,494
Fair Value, Recurring [Member] | Money Market Funds [Member]
Cash equivalents	14,021	11,416
Fair Value, Recurring [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	24,663	26,047
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member]
Assets	23,398	26,467
Contingent consideration - business combinations	0	0
Debt	0	0
Liabilities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	9,377	15,051
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Other Debt Obligations [Member]
Marketable debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Money Market Funds [Member]
Cash equivalents	14,021	11,416
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member]
Assets	28,422	29,541
Contingent consideration - business combinations	0	0
Debt	24,942	25,607
Liabilities	24,942	25,607
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Other Debt Obligations [Member]
Marketable debt securities	3,759	3,494
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Money Market Funds [Member]
Cash equivalents	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	24,663	26,047
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member]
Assets	0	0
Contingent consideration - business combinations	5,176	4,456
Debt	0	0
Liabilities	5,176	4,456
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | US Government Agencies Debt Securities [Member]
Marketable debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Other Debt Obligations [Member]
Marketable debt securities	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Money Market Funds [Member]
Cash equivalents	0	0
Fair Value, Recurring [Member] | Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities, Cash Equivalents [Member]
Cash equivalents	$ 0	$ 0

Note 3 - Fair Value Measureme_5

Note 3 - Fair Value Measurement - Fair Value of Contingent Consideration Using Level 3 Inputs (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Change in fair value recognized in net loss	$ 720	$ (3,335)
Contingent Consideration Liabilities [Member]
Balance	4,456,000	10,027,000
Balance	$ 5,176,000	$ 6,692,000

Note 4 - Investments (Details T

Note 4 - Investments (Details Textual) - Contingent Convertible Preferred Stock [Member] - USD ($)	Mar. 31, 2023	Dec. 31, 2022
Series A-1 and A-2, Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 4,100,000
Series E Preferred Stock [Member]
Equity Securities without Readily Determinable Fair Value, Amount	$ 995,000	$ 995,000

Note 4 - Investments - Availabl

Note 4 - Investments - Available-For-Sale Marketable Securities (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Debt Securities, Available-for-Sale, Amortized Cost, Current	$ 35,792
Debt Securities, Available-for-Sale, Unrealized Gain, Current	7
Debt Securities, Available-for-Sale, Unrealized Loss, Current	19
Available-for-sale securities, current portion	35,780	$ 43,260
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	2,018
Available-for-sale securities, long-term	2,019	1,332
Debt Securities, Available-for-Sale, Amortized Cost, Total	37,810
Debt Securities, Available-for-Sale, Unrealized Gain	9
Debt Securities, Available-for-Sale, Unrealized Loss	20
Debt Securities, Available-for-Sale, Total	37,799
Due in one year or less, amortized cost	35,792
Due in one year or less, fair value	35,780	$ 43,260
Due after one year through five years, amortized cost	2,018
Due after one year through five years, fair value	2,019
Total, amortized cost	37,810
Marketable debt securities	37,799
US Government Agencies Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	9,386
Debt Securities, Available-for-Sale, Unrealized Gain, Current	0
Debt Securities, Available-for-Sale, Unrealized Loss, Current	9
Available-for-sale securities, current portion	9,377
Due in one year or less, amortized cost	9,386
Due in one year or less, fair value	9,377
Corporate Debt Securities [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	24,663
Debt Securities, Available-for-Sale, Unrealized Gain, Current	7
Debt Securities, Available-for-Sale, Unrealized Loss, Current	7
Available-for-sale securities, current portion	24,663
Due in one year or less, amortized cost	24,663
Due in one year or less, fair value	24,663
Other Debt Obligations [Member]
Debt Securities, Available-for-Sale, Amortized Cost, Current	1,743
Debt Securities, Available-for-Sale, Unrealized Gain, Current	0
Debt Securities, Available-for-Sale, Unrealized Loss, Current	3
Available-for-sale securities, current portion	1,740
Debt Securities, Available-for-Sale, Amortized Cost, NoncurrentDebt Securities, Available-for-Sale, Amortized Cost, Noncurrent	2,018
Debt Securities, Available-for-Sale, Unrealized Gain, Noncurrent	2
Debt Securities, Available-for-Sale, Unrealized Loss, Noncurrent	1
Available-for-sale securities, long-term	2,019
Due in one year or less, amortized cost	1,743
Due in one year or less, fair value	1,740
Due after one year through five years, amortized cost	$ 2,018

Note 5 - Inventories - Summary

Note 5 - Inventories - Summary of Inventories (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Raw materials	$ 23,682	$ 20,950
Work in progress	6,934	5,680
Finished goods	10,713	8,274
Total	$ 41,329	$ 34,904

Note 6 - Leases (Details Textua

Note 6 - Leases (Details Textual)	Mar. 31, 2023
Real Estate Lease[Member] | Minimum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	1 year
Lessee, Operating Lease, Renewal Term (Year)	1 year
Real Estate Lease[Member] | Maximum [Member]
Lessee, Operating Lease, Remaining Lease Term (Year)	10 years
Lessee, Operating Lease, Renewal Term (Year)	5 years
Vehicle and Other Equipment {[Member] | Minimum [Member]
Lessee, Operating Lease, Term of Contract (Year)	1 year
Vehicle and Other Equipment {[Member] | Maximum [Member]
Lessee, Operating Lease, Term of Contract (Year)	5 years

Note 6 - Leases - Lease Term an

Note 6 - Leases - Lease Term and Discount Rate (Details)	Mar. 31, 2023	Dec. 31, 2022
Weighted average discount rate - operating leases	4.30%	4.20%
Weighted average discount rate - finance leases	6.10%	6.10%
Weighted average remaining lease term in years - operating leases (Year)	6 years 10 months 24 days	7 years 2 months 12 days
Weighted average remaining lease term in years - finance leases (Year)	1 year 9 months 18 days	2 years

Note 6 - Leases - Components of

Note 6 - Leases - Components of Lease Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating lease costs	$ 897	$ 913
Short-term lease costs	402	565
Total operating lease costs	1,299	1,478
Variable lease costs	259	305
Total lease costs	$ 1,558	$ 1,783

Note 6 - Leases - Maturities of

Note 6 - Leases - Maturities of Lease Liabilities (Details) $ in Thousands	Mar. 31, 2023 USD ($)
2023 (9 months remaining), operating leases	$ 2,690
2023 (9 months remaining), finance leases	128
2024, operating leases	3,398
2024, finance leases	101
2025, operating leases	2,954
2025, finance leases	38
2026, operating leases	2,533
2026, finance leases	2
2027, operating leases	2,280
2027, finance leases	0
Thereafter, operating leases	6,938
Thereafter, finance leases	0
Total operating lease payments	20,793
Total financing lease payments, finance leases	269
Less: operating lease interest	(2,773)
Less: financing lease interest	(13)
Total present value of operating lease liabilities	18,020
Total present value of financing lease liabilities	$ 256

Note 7 - Assets Held for Rent_2

Note 7 - Assets Held for Rent (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Assets Held for Rent, Depreciation	$ 843,000	$ 896,000

Note 7 - Assets Held for Rent -

Note 7 - Assets Held for Rent - Assets Held for Rent (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Shippers placed in service	$ 8,132	$ 7,671
Fixed assets held for rent	4,686	4,686
Accumulated depreciation	(5,451)	(4,952)
Subtotal	7,367	7,405
Shippers and related components in production	1,638	1,659
Total	$ 9,005	$ 9,064

Note 8 - Property and Equipme_3

Note 8 - Property and Equipment (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Depreciation	$ 878,000	$ 757,000

Note 8 - Property and Equipme_4

Note 8 - Property and Equipment - Property and Equipment (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Property and equipment	$ 35,723	$ 32,809
Less: Accumulated depreciation	(9,623)	(9,171)
Property and equipment, net	26,100	23,638
Leasehold Improvements [Member]
Property and equipment	5,110	5,249
Furniture and Computer Equipment [Member]
Property and equipment	1,954	1,908
Manufacturing Facility [Member]
Property and equipment	21,278	20,557
Construction in Progress [Member]
Property and equipment	$ 7,381	$ 5,095

Note 9 - Goodwill and Intangi_3

Note 9 - Goodwill and Intangible Assets (Details Textual) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Amortization of Intangible Assets	$ 1,459	$ 2,863

Note 9 - Goodwill and Intangi_4

Note 9 - Goodwill and Intangible Assets - Intangible Assets (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Accumulated Amortization	$ (23,469)	$ (22,010)
Net Carrying Value	30,629
Total intangible assets, gross	54,098	54,098
Total intangible assets, net	$ 30,629	$ 32,088
Weighted Average [Member]
Weighted Average Useful Life (Year)	8 years	8 years 2 months 12 days
Customer Relationships [Member]
Gross Carrying Value	$ 11,288	$ 11,288
Accumulated Amortization	(4,446)	(3,993)
Net Carrying Value	$ 6,842	$ 7,295
Customer Relationships [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	9 years 1 month 6 days	9 years 3 months 18 days
Trade Names [Member]
Gross Carrying Value	$ 13,731	$ 13,731
Accumulated Amortization	(4,556)	(4,323)
Net Carrying Value	$ 9,175	$ 9,408
Trade Names [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	12 years 7 months 6 days	12 years 9 months 18 days
Technology-Based Intangible Assets [Member]
Gross Carrying Value	$ 27,892	$ 27,892
Accumulated Amortization	(13,528)	(12,796)
Net Carrying Value	$ 14,364	$ 15,096
Technology-Based Intangible Assets [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	4 years 7 months 6 days	4 years 10 months 24 days
Noncompete Agreements [Member]
Gross Carrying Value	$ 1,187	$ 1,187
Accumulated Amortization	(939)	(898)
Net Carrying Value	$ 248	$ 289
Noncompete Agreements [Member] | Weighted Average [Member]
Weighted Average Useful Life (Year)	1 year 9 months 18 days	2 years

Note 9 - Goodwill and Intangi_5

Note 9 - Goodwill and Intangible Assets - Future Amortization Expense (Details) $ in Thousands	Mar. 31, 2023 USD ($)
2023 (9 months remaining)	$ 3,972
2024	4,607
2025	4,435
2026	4,137
2027	3,383
Thereafter	10,095
Total	$ 30,629

Note 10 - Accrued Expenses an_3

Note 10 - Accrued Expenses and Other Current Liabilities - Accrued Expenses and Other Current Liabilities (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022	Mar. 31, 2022
Accrued compensation	$ 5,306	$ 5,080
Accrued expenses	3,825	3,128
Deferred revenue, current	422	548
Accrued taxes	1,148	975
Other	0	51
Total accrued expenses and other current liabilities	$ 10,701	$ 9,782	$ 6,733

Note 11 - Warranty Reserve Li_3

Note 11 - Warranty Reserve Liability (Details Textual)	3 Months Ended
	Mar. 31, 2022 USD ($)
Standard Product Warranty Accrual, Increase (Decrease) for Preexisting Warranties	$ 525,000

Note 11 - Warranty Reserve Li_4

Note 11 - Warranty Reserve Liability - Warranty Reserve Liability (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2023	Mar. 31, 2022
Balance		$ 8,312	$ 9,398
Provision for warranties	[1]	1,891	1,419
Settlements of warranty claims	[1]	(1,308)	(1,641)
Balance		$ 8,895	$ 9,176
[1]Both the Provision for warranties and Settlements of warranty claims balances during the three months ended March 31, 2022 include reclassifications of $525,000 to reflect changes in warranty utilization on pre-existing claims

Note 12 - Commitments and Con_2

Note 12 - Commitments and Contingencies (Details Textual) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Sales and Excise Tax Payable	$ 4,400,000	$ 3,700,000
Sales Taxes Assessed	$ 230,000	$ 306,000

Note 13 - Long-term Debt (Detai

Note 13 - Long-term Debt (Details Textual) - The 2022 Term Loan 3 [Member] - USD ($) $ in Millions	Sep. 20, 2022	Mar. 31, 2023
Debt Instrument, Maximum Borrowing Capacity	$ 50
Debt Instrument, Maximum Borrowing Capacity at Closing	30	$ 30
Debt Instrument, Additional Maximum Amount Within Nine Months After Closing	10
Debt Instrument, Additional Maximum Amount Upon Certain Milestone Acheivements	10
Debt Instrument, Additional Maximum At Discretion of Lender	10
Debt Instrument, Face Amount	$ 20	$ 20
Debt Instrument, Interest Rate, Maximum Stated Percentage for Each Tranche Borrowed	1%
Prime Rate [Member]
Debt Instrument, Basis Spread on Variable Rate	0.50%

Note 13 - Long-term Debt - Long

Note 13 - Long-term Debt - Long-term Debt (Details) - USD ($) $ in Thousands	Mar. 31, 2023		Dec. 31, 2022
Debt, carrying amount	$ 25,091		$ 25,786
Less: unamortized debt issuance costs	(149)		(179)
Total debt	24,942		25,607
Less: current portion	(1,250)		(1,814)
Total long-term debt	$ 23,692		23,793
The 2022 Term Loan 1 [Member]
Interest rate	4%
Debt, carrying amount	$ 2,896	[1]	2,896
The 2022 Term Loan 2 [Member]
Interest rate	6.80%
Debt, carrying amount	$ 20,000		20,000
Financed Insurance Premium [Member]
Interest rate	5%
Debt, carrying amount	$ 505		1,074
Freezer Equipment Loan [Member]
Interest rate	5.70%
Debt, carrying amount	$ 430		466
Manufacturing Equipment Loans [Member]
Interest rate	5.70%
Debt, carrying amount	$ 243		266
Freezer Installation Loan [Member]
Interest rate	6.30%
Debt, carrying amount	$ 1,012		1,078
Other Loans [Member]
Debt, carrying amount	5		6
Total Debt [Member]
Total long-term debt	$ 23,692		$ 23,793
[1](1) 2022 term loan 1 carried a maturity date of September 2024 as of the year ended December 31, 2021. As of September 30, 2022, the entirety of the outstanding principal and accrued interest was repaid.

Note 13 - Long-term Debt - Matu

Note 13 - Long-term Debt - Maturities of Loans Payable (Details) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
2023 (9 months remaining)	$ 1,135
2024	5,481
2025	10,511
2026	5,219
2027	2,596
Thereafter	0
Total debt	$ 24,942	$ 25,607

Note 14 - Revenue (Details Text

Note 14 - Revenue (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Deferred Revenue	$ 422,000	$ 558,000
Deferred Revenue, Revenue Recognized	$ 242,000

Note 14 - Revenue - Revenues by

Note 14 - Revenue - Revenues by Product Line (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Total revenue	$ 37,703	$ 36,220
Product, Freezer and Thaw [Member]
Total revenue	12,381	15,335
Product, Cell Processing [Member]
Total revenue	18,993	14,899
Storage and Storage Services Product Revenue [Member]
Total revenue	219	154
Storage and Storage Services [Member]
Total revenue	3,825	3,090
Service, Freezer and Thaw [Member]
Total revenue	646	0
Storage and Storage Services Rental Revenue [Member]
Total revenue	$ 1,639	$ 2,742

Note 14 - Revenue - Summary of

Note 14 - Revenue - Summary of Remaining Performance Obligations (Details) $ in Millions	Mar. 31, 2023 USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 3.6
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 0.2

Note 14 - Revenue - Summary o_2

Note 14 - Revenue - Summary of Remaining Performance Obligations 2 (Details) $ in Thousands	Mar. 31, 2023 USD ($)
Rental Revenue [Member]
Service revenue, expected to be recognized in the future	$ 3,600
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Service revenue, expected to be recognized in the future	$ 2,700
Service revenue, expected to be recognized in the future, period (Year)	9 months
Rental Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 900
Service revenue, expected to be recognized in the future, period (Year)	1 year
Service Revenue [Member]
Service revenue, expected to be recognized in the future	$ 200
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Service revenue, expected to be recognized in the future	$ 190
Service revenue, expected to be recognized in the future, period (Year)	9 months
Service Revenue [Member] | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Service revenue, expected to be recognized in the future	$ 10
Service revenue, expected to be recognized in the future, period (Year)	1 year

Note 15 - Stock-based Compens_3

Note 15 - Stock-based Compensation (Details Textual) - USD ($)				3 Months Ended
	Jan. 08, 2023	Feb. 24, 2022	Feb. 08, 2021	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement, Expense				$ 7,363,000	$ 5,399,000
Share-Based Payment Arrangement, Option [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value				7,300,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value				$ 1,600,000	3,600,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				0
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term (Year)				2 years 8 months 12 days
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 0
Restricted Stock [Member]
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				46,100,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value				7,300,000	7,900,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value				7,300,000	5,000,000
Share-Based Payment Arrangement, Expense				$ 6,100,000	4,800,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				2 years 8 months 12 days
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)				414,601
Market-based Restricted Stock [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)				268,738
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount				$ 8,200,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Fair Value			$ 1,300,000
Share-Based Payment Arrangement, Expense				$ 1,300,000	605,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)				1 year 6 months
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards			100%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Historical Volatility Rate	78%	63%	68%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0%	0%	0%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	4.40%	1.50%	0.10%
Share Based Compensation Arrangement By Share Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Period (Year)	2 years	2 years	2 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Aggregate Fair Value				$ 6,500,000	6,700,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested				$ 666,000	$ 5,000,000
Market-based Restricted Stock [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	0%	0%
Market-based Restricted Stock [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Awards	200%	200%
Market-based Restricted Stock [Member] | Executive Officer [Member]
Share-Based Payment Arrangement, Expense	$ 6,800,000	$ 6,700,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in shares)	268,738	240,428	30,616

Note 15 - Share-based Compensat

Note 15 - Share-based Compensation - Stock Option Activity (Details) - Share-Based Payment Arrangement, Option [Member]	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Outstanding (in shares) | shares	456,293
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.16
Exercised (in shares) | shares	(80,938)
Exercised, weighted average exercise price (in dollars per share) | $ / shares	$ 2.06
Outstanding as of March 31, 2023 (in shares) | shares	375,355
Outstanding, weighted average exercise price (in dollars per share) | $ / shares	$ 2.18
Stock options exercisable as of March 31, 2023 (in shares) | shares	375,355
Options exercisable, weighted average exercise price (in dollars per share) | $ / shares	$ 2.18

Note 15 - Share-based Compens_2

Note 15 - Share-based Compensation - Restricted Stock Activity (Details)	3 Months Ended
	Mar. 31, 2023 $ / shares shares
Restricted Stock [Member]
Outstanding, shares (in shares) | shares	1,879,215
Outstanding, weighted Average Exercise Price (in dollars per share) | $ / shares	$ 28.94
Granted (in shares) | shares	414,601
Granted (in dollars per share) | $ / shares	$ 17.67
Vested (in shares) | shares	(346,184)
Vested (in dollars per share) | $ / shares	$ 27.51
Forfeited (in shares) | shares	(70,725)
Forfeited (in dollars per share) | $ / shares	$ 29.67
Outstanding, shares (in shares) | shares	1,876,907
Outstanding, weighted Average Exercise Price (in dollars per share) | $ / shares	$ 26.69
Market-based Restricted Stock [Member]
Outstanding, shares (in shares) | shares	271,044
Outstanding, weighted Average Exercise Price (in dollars per share) | $ / shares	$ 30.64
Granted (in dollars per share) | $ / shares	$ 24.23
Vested (in shares) | shares	(30,616)
Vested (in dollars per share) | $ / shares	$ 51.65
Outstanding, shares (in shares) | shares	509,166
Outstanding, weighted Average Exercise Price (in dollars per share) | $ / shares	$ 26
Granted (in shares) | shares	268,738

Note 15 - Share-based Compens_3

Note 15 - Share-based Compensation - Stock Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Stock compensation expense	$ 7,363	$ 5,399
Cost of Sales [Member]
Stock compensation expense	1,631	1,007
General and Administrative Expense [Member]
Stock compensation expense	3,293	3,010
Selling and Marketing Expense [Member]
Stock compensation expense	1,256	705
Research and Development Expense [Member]
Stock compensation expense	$ 1,183	$ 677

Note 16 - Income Taxes (Details

Note 16 - Income Taxes (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Sep. 30, 2022
Income Tax Expense (Benefit), Total	$ 92,000	$ (599,000)	$ (92,000,000,000)
Effective Income Tax Rate Reconciliation, Percent, Total			0.70%
Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-Based Payment Arrangement, Amount			$ 505,000
Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount			$ 1.1
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21%
Deferred Tax Assets, Valuation Allowance	$ 40,100,000

Note 17 - Net (Loss) Income P_3

Note 17 - Net (Loss) Income Per Common Share - Calculation of Diluted Shares (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net (loss) income	$ (13,714)	$ (7,421)
Net loss allocated to common shareholders	$ (13,714)	$ (7,421)
Basic and Diluted (in shares)	43,027,612	42,014,055
Basic and Diluted (in dollars per share)	$ (0.32)	$ (0.18)

Note 17 - Net (Loss) Income Com

Note 17 - Net (Loss) Income Common Share - Anti-dilutive Securities Excluded From Computation (Details) - shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Anti-dilutive securities (in shares)	3,153,029	2,094,863
Share-based Payment Arrangement, Option and Restricted Stock Awards [Member]
Anti-dilutive securities (in shares)	3,153,029	2,094,863

Note 18 - Employee Benefit Pl_2

Note 18 - Employee Benefit Plan (Details Textual) - Defined Contribution Plan, 401 K [Member] - Pension Plan [Member] - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	100%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 311,000	$ 226,000